Stock Track | Maravai LifeSciences Plunges 7.27% Following Q3 Revenue Miss and Weak Guidance

Stock Track11-07

Shares of Maravai LifeSciences Holdings, Inc. (MRVI) experienced a significant 24-hour plunge of 7.27% during Friday's trading session, as investors reacted to the company's disappointing third-quarter financial results and lowered full-year guidance.

The biotechnology company reported Q3 revenue of $41.6 million, falling short of analyst expectations of $49 million and representing a 39.7% year-over-year decline. The miss was primarily attributed to weakness in the nucleic acid production segment, which saw a 52.9% decrease in revenue due to a lack of high-volume CleanCap orders and non-recurring large GMP orders. Additionally, Maravai's adjusted EBITDA for the quarter came in at -$10.8 million, missing the consensus estimate of -$7.41 million.

Adding to investor concerns, Maravai provided full-year 2025 revenue guidance of approximately $185 million, which may be viewed as conservative by market participants. Despite the challenges, the company highlighted some positive developments, including a 7.2% year-over-year growth in its Biologics Safety Testing segment and ongoing organizational restructuring and cost reduction initiatives. Management expressed optimism for the fourth quarter, anticipating double-digit sequential revenue growth for its TriLink business unit and aiming for improved financial results in Q4 2025 and into 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103830882?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 15:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103830882","market":"sg","top_or_hot":-1,"title":"Stock Track | Maravai LifeSciences Plunges 7.27% Following Q3 Revenue Miss and Weak Guidance","media":"Stock Track","content":"<p>Shares of Maravai LifeSciences Holdings, Inc. (MRVI) experienced a significant 24-hour plunge of 7.27% during Friday's trading session, as investors reacted to the company's disappointing third-quarter financial results and lowered full-year guidance.</p>\n\n<p>The biotechnology company reported Q3 revenue of $41.6 million, falling short of analyst expectations of $49 million and representing a 39.7% year-over-year decline. The miss was primarily attributed to weakness in the nucleic acid production segment, which saw a 52.9% decrease in revenue due to a lack of high-volume CleanCap orders and non-recurring large GMP orders. Additionally, Maravai's adjusted EBITDA for the quarter came in at -$10.8 million, missing the consensus estimate of -$7.41 million.</p>\n\n<p>Adding to investor concerns, Maravai provided full-year 2025 revenue guidance of approximately $185 million, which may be viewed as conservative by market participants. Despite the challenges, the company highlighted some positive developments, including a 7.2% year-over-year growth in its Biologics Safety Testing segment and ongoing organizational restructuring and cost reduction initiatives. Management expressed optimism for the fourth quarter, anticipating double-digit sequential revenue growth for its TriLink business unit and aiming for improved financial results in Q4 2025 and into 2026.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Maravai LifeSciences Plunges 7.27% Following Q3 Revenue Miss and Weak Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Maravai LifeSciences Plunges 7.27% Following Q3 Revenue Miss and Weak Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 15:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Maravai LifeSciences Holdings, Inc. (MRVI) experienced a significant 24-hour plunge of 7.27% during Friday's trading session, as investors reacted to the company's disappointing third-quarter financial results and lowered full-year guidance.</p>\n\n<p>The biotechnology company reported Q3 revenue of $41.6 million, falling short of analyst expectations of $49 million and representing a 39.7% year-over-year decline. The miss was primarily attributed to weakness in the nucleic acid production segment, which saw a 52.9% decrease in revenue due to a lack of high-volume CleanCap orders and non-recurring large GMP orders. Additionally, Maravai's adjusted EBITDA for the quarter came in at -$10.8 million, missing the consensus estimate of -$7.41 million.</p>\n\n<p>Adding to investor concerns, Maravai provided full-year 2025 revenue guidance of approximately $185 million, which may be viewed as conservative by market participants. Despite the challenges, the company highlighted some positive developments, including a 7.2% year-over-year growth in its Biologics Safety Testing segment and ongoing organizational restructuring and cost reduction initiatives. Management expressed optimism for the fourth quarter, anticipating double-digit sequential revenue growth for its TriLink business unit and aiming for improved financial results in Q4 2025 and into 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRVI","symbol_name":"Maravai LifeSciences Holdings, Inc.","start_time":0,"source_url":"","article_id":"1103830882","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103830882","pubTimestamp":1762500762,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Maravai LifeSciences Holdings, Inc. (MRVI) experienced a significant 24-hour plunge of 7.27% during Friday's trading session, as investors reacted to the company's disappointing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRVI":"Maravai LifeSciences Holdings, Inc."},"translate_title":"股票追踪|Maravai LifeSciences在第三季度营收未达预期和指引疲弱后暴跌7.27%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRVI":1},"content_text":"Shares of Maravai LifeSciences Holdings, Inc. (MRVI) experienced a significant 24-hour plunge of 7.27% during Friday's trading session, as investors reacted to the company's disappointing third-quarter financial results and lowered full-year guidance.\nThe biotechnology company reported Q3 revenue of $41.6 million, falling short of analyst expectations of $49 million and representing a 39.7% year-over-year decline. The miss was primarily attributed to weakness in the nucleic acid production segment, which saw a 52.9% decrease in revenue due to a lack of high-volume CleanCap orders and non-recurring large GMP orders. Additionally, Maravai's adjusted EBITDA for the quarter came in at -$10.8 million, missing the consensus estimate of -$7.41 million.\nAdding to investor concerns, Maravai provided full-year 2025 revenue guidance of approximately $185 million, which may be viewed as conservative by market participants. Despite the challenges, the company highlighted some positive developments, including a 7.2% year-over-year growth in its Biologics Safety Testing segment and ongoing organizational restructuring and cost reduction initiatives. Management expressed optimism for the fourth quarter, anticipating double-digit sequential revenue growth for its TriLink business unit and aiming for improved financial results in Q4 2025 and into 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103830882","isCrawlerRequest":true}